Wegovy for Women: Evidence, Eligibility, Coverage
Wegovy has no separate rule for women. It is approved for weight loss, heart risk and MASH liver disease. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- Active ingredient
- semaglutide
- How it is taken
- weekly injection or daily tablet
- Approved for
- Weight loss, heart risk and MASH liver disease
- Best result (STEP 1)
- 14.9% weight loss
Wegovy overview
Its half-life is about 1 week. After 7 d, half is gone, and about 3% remains after five half-lives (35 d).
In STEP 1 at 68 weeks, people lost 14.9% of body weight, compared with 2.4% on placebo.
Monthly prices in US dollars include the list price and self-pay offers. Each comes from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | For adults who have either obesity or overweight along with heart disease, it lowers the risk of heart attack, stroke, or death caused by the heart, with injection and tablet forms. |
| FDA label | Long term weight loss and keeping it off, with diet and activity, for children 12 and older and adults who have obesity, or for adults with overweight plus a weight-related condition. |
| FDA label | When given by injection, this medicine treats MASH liver disease for adults with scarring that is moderate to advanced, provided they have no cirrhosis. |
| FDA label | In adults, the tablet form is approved to help with weight loss and heart risk. |
| Medicare GLP-1 Bridge | BMI 35 or higher, no condition needed |
| Medicare GLP-1 Bridge | Qualification requires BMI 30 or higher plus one of the following: heart failure, CKD 3a+, or uncontrolled blood pressure |
| Medicare GLP-1 Bridge | You need BMI 27 or higher plus one of the following: a prior heart attack or stroke, prediabetes, or PAD |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | start by completing 6 months in a diet and activity program |
The list of sources includes aetna.com, medicare.gov 1 and 2, together with FDA label (DailyMed).
Trial results for women
None of the trials enrolled women alone. Adults with obesity or overweight took part, and none of them had diabetes.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 | Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Trial source: STEP 1 (FDA label (DailyMed)).
What is different for women?
| What changes | What the label says |
|---|---|
| Acute Gallbladder Disease | Gallstones and gallbladder inflammation can happen. Report yellow skin or eyes, fever, or upper right belly pain. |
The FDA labels state this: DailyMed FDA label.
These label warnings come from the FDA label (DailyMed).
Coverage for women
Medicare Part D does not cover a GLP-1 when you use it only for weight loss.
People who meet the rules of Medicare GLP-1 Bridge can find Wegovy listed at $50 per month.
Wherever Medicaid covers weight-loss GLP-1s, prior authorization is the standard.
Sources: humana.com, CMS, KFF.
- Wegovy Coupon and Savings Card
- Wegovy Cost
- Wegovy Cost Without Insurance
- Wegovy Cost With Insurance
- Cheapest Way to Get Wegovy
- Wegovy Patient Assistance
- Is Wegovy Covered by Insurance? Criteria, Copay, Appeal
- Does Medicare Cover Wegovy? Criteria, Copay, How to Appeal
- Does BCBS Cover Wegovy? Coverage by State Plan, PA Rules, Appeals
Alternatives for women
| Medicine | For women | How it is taken | Trial result |
|---|---|---|---|
| Wegovy | Approved uses apply | weekly injection or daily tablet | 14.9% weight loss |
 Ozempic | Approved uses apply | weekly injection | Not listed |
 Rybelsus | Approved uses apply | daily tablet | Not listed |
 Mounjaro | Approved uses apply | weekly injection | Not listed |
 Zepbound | Approved uses apply | weekly injection | 20.9% weight loss |
 Foundayo | Approved uses apply | daily tablet | 11.1% weight loss |
 Trulicity | Approved uses apply | weekly injection | Not listed |
 Saxenda | Approved uses apply | daily injection | 7.4% weight loss |
 Victoza | Approved uses apply | daily injection | Not listed |
| Byetta | Approved uses apply | twice-daily injection | Not listed |
Sources: FDA label (DailyMed).
Questions to ask your prescriber
- Will this medicine affect my birth control?
- When should I stop before I try to get pregnant?
For full details, read the complete Wegovy prescribing information on DailyMed.